Skip to Content

Zantac EFFERdose (ranitidine) Disease Interactions

There are 6 disease interactions with Zantac EFFERdose (ranitidine):

Major

H2 antagonists (Includes Zantac EFFERdose) ↔ GI bleeding

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

Major

Ranitidine (Includes Zantac EFFERdose) ↔ porphyria

Severe Potential Hazard, Moderate plausibility. Applies to: Porphyria

Ranitidine may rarely precipitate acute porphyria attacks and should be avoided in patients with a history of acute porphyria.

References

  1. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Ranitidine (Includes Zantac EFFERdose) ↔ hemodialysis

Moderate Potential Hazard, High plausibility. Applies to: hemodialysis

Ranitidine is partially removed by hemodialysis and should be administered after dialysis.

References

  1. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
  2. Garg DC, Baltodano N, Perez GO, et al "Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients." Pharmacology 31 (1985): 189-93
  3. Comstock TJ, Sica DA, Harford A, Eshelman F "Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis." Nephron 52 (1989): 15-9
Moderate

Ranitidine (Includes Zantac EFFERdose) ↔ liver disease

Moderate Potential Hazard, Low plausibility. Applies to: Liver Disease

Ranitidine is partially metabolized by the liver. Although dosage reductions are generally not necessary, therapy with ranitidine should be administered cautiously in patients with liver disease. Elevated ALT (SGPT) has been observed in patients receiving ranitidine intravenously at dosages greater than those normally recommended for 5 days or more.

References

  1. Morichau-Beauchant M, Houin G, Mavier P, et al "Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients." Dig Dis Sci 31 (1986): 113-8
  2. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
  3. Smith IL, Ziemniak JA, Bernhard H, et al "Ranitidine disposition and systemic availability in hepatic cirrhosis." Clin Pharmacol Ther 35 (1984): 487-94
  4. Gonzalez-Martin G, Paulos C, Veluso B, et al "Ranitidine disposition in severe hepatic cirrhosis." Int J Clin Pharmacol Ther Toxicol 25 (1987): 139-42
  5. Young CJ, Daneshmend TK, Roberts CJC "Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine." Gut 23 (1982): 819-23
  6. Okolicsanyi L, Venuti M, Strazzabosco M, et al "Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis." Int J Clin Pharmacol Ther Toxicol 22 (1984): 329-32
View all 6 references
Moderate

Ranitidine (Includes Zantac EFFERdose) ↔ PKU

Moderate Potential Hazard, High plausibility. Applies to: Phenylketonuria

Zantac (brand of ranitidine) 150 EFFERdose tablets and granules both contain 16.84 mg of phenylalanine per each 150 mg of ranitidine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

References

  1. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Ranitidine (Includes Zantac EFFERdose) ↔ renal dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Ranitidine is primarily eliminated by the kidney. Although the drug is generally well-tolerated, the daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution.

References

  1. McFayden ML, Folb PI, Miller R, et al "Pharmacokinetics of ranitidine in patients with chronic renal failure." Eur J Clin Pharmacol 25 (1983): 347-51
  2. Meffin PJ, Grgurinovich N, Brooks PM, et al "Ranitidine disposition in patients with renal impairment." Br J Clin Pharmacol 16 (1983): 731-4
  3. McGonigle RJ, Williams LC, Amphlett GE, et al "The pharmacokinetics of ranitidine in renal disease." Pharmacokinet Pharmacodynam (1982): 41-7
  4. Dixon JS, Borgcostanzi JM, Langley SJ, Lacey LF, Toon S "The effect of renal function on the pharmacokinetics of ranitidine." Eur J Clin Pharmacol 46 (1994): 167-71
  5. Zech PY, Chau NP, Pozet N, et al "Ranitidine kinetics in chronic renal impairment." Clin Pharmacol Ther 34 (1983): 667-72
  6. Kopitar Z, Cvelbar P, Zorz M, et al "Pharmacokinetics of ranitidine in adult patients with end stage renal disease after single and multiple dosing." Acta Pharm Juglosl 37 (1987): 371-9
  7. Garg DC, Baltodano N, Jallad NS, et al "Pharmacokinetics of ranitidine in patients with renal failure." J Clin Pharmacol 26 (1986): 286-91
  8. Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
  9. "Product Information. Zantac (ranitidine)." Glaxo Wellcome, Research Triangle Park, NC.
View all 9 references

Zantac EFFERdose (ranitidine) drug interactions

There are 323 drug interactions with Zantac EFFERdose (ranitidine)

Zantac EFFERdose (ranitidine) alcohol/food interactions

There is 1 alcohol/food interaction with Zantac EFFERdose (ranitidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide